Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
22 Results for "
Peptide-linker conjugate
" in MedChemExpress (MCE) Product Catalog:
Products (22)
22 Results for "Peptide-linker conjugate" in MCE Product Catalog:
33
33 Publications Verification
Synonyms: MC-GGFG-DXD
Target:
Research Areas:
Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .
12
12 Cited Publications
Synonyms: T-DXd (solution); DS-8201 (solution); DS-8201a (solution)
Target:
Research Areas:
Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
12
12 Cited Publications
Synonyms: T-DXd; DS-8201; DS-8201a
Target:
Research Areas:
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
Cat. No.: HY-13631ES4
Synonyms: MC-GGFG-DXD-d5
Cat. No.: HY-13631EG
CAS No.: 1599440-13-7
Synonyms: MC-GGFG-DXD (GMP)
Cat. No.: HY-P4154
CAS No.: 2276787-79-0
Synonyms: ALM-488
Target:
Research Areas:
Cat. No.: HY-160807
CAS No.: 2769152-95-4
Target:
Research Areas:
DBM-GGFG-NH-O-CO-Exatecan (Example 4, Compound 14) is a conjugate of an ADC drug toxin molecule and a linker. DBM-GGFG-NH-O-CO-Exatecan is a complete antibody-drug conjugate intermediate that integrates a potent camptothecin-based toxin, a cleavable peptide linker (GGFG), and a reactive terminus that can directly conjugate to antibodies .
Cat. No.: HY-176806
CAS No.: 606967-53-7
Synonyms: Doxorubicin-LNAA-Boc
Target:
Research Areas:
Legubicin (Doxorubicin-LNAA-Boc) is a novel conjugate of Doxorubicin (HY-15142A) and a Legumain-cleavable peptide linker. Legubicin is activated by Legumain to release leucine-doxorubicin while sparing normal tissues. Legubicin inhibits tumor cell growth and reduces DNA binding in non-legumain expressing cells. Legubicin completely arrests tumor growth in mice bearing CT26 tumors. Legubicin can be used for the study of colon carcinoma (CRC) .
Cat. No.: HY-13631ES3
CAS No.: 2760715-87-3
Synonyms: MC-GGFG-DXD-d2
Cat. No.: HY-13631ES
CAS No.: 2760715-91-9
Synonyms: MC-GGFG-DXD-d4
Cat. No.: HY-147021
CAS No.: 1350456-66-4
Target:
Research Areas:
MC-Val-D-Cit-PAB-PNP is a peptide linker that can be used for the synthesis of Antibody-Drug Conjugates (ADCs). MC-Val-D-Cit-PAB-PNP can be used to construct antibody-drug conjugates loaded with ATR/CHK1 inhibitors .
Cat. No.: HY-13631ES2
CAS No.: 2760715-88-4
Synonyms: MC-GGFG-DXD-d4-1
Cat. No.: HY-158199
CAS No.: 2126749-95-7
Target:
Research Areas:
BCN-HS-PEG2-bis(PNP) is a p-nitrophenyl ADC linker that can be used for further coupling of ADC toxins with peptide linkers. BCN-HS-PEG2-bis(PNP) can be combined with vc-PABC-MMAE (HY-15162) to form drug-linker conjugates for ADCs.
Cat. No.: HY-P11030
Target:
Research Areas:
Cat. No.: HY-128941
CAS No.: 1452145-13-9
Target:
Research Areas:
CCK2R Ligand-Linker Conjugates 1 is a ligand-linker conjugate, which conjugates to the cytotoxic antimicrotubule agents Desacetyl Vinblastine Hydrazide (DAVBH) and Tubulysin B Hydrazide (TubBH) via a hydrophilic peptide linker .
Cat. No.: HY-147021A
CAS No.: 1350456-64-2
Target:
Research Areas:
MC-D-Val-Cit-PAB-PNP is a peptide linker that can be used for the synthesis of Antibody-Drug Conjugates (ADCs). MC-D-Val-Cit-PAB-PNP can be used to construct antibody-drug conjugates loaded with ATR/CHK1 inhibitors .
Cat. No.: HY-138298B
CAS No.: 1826843-81-5
Synonyms: T-DXd (DAR2); DS-8201 (DAR2); DS-8201a (DAR2)
Target:
Research Areas:
Trastuzumab deruxtecan (DAR2) (T-DXd (DAR2); DS-8201 (DAR2); DS-8201a (DAR2)) is a low-drug-load derivative control preparation of Trastuzumab deruxtecan (HY-138298A) with a drug-to-antibody ratio (DAR) of 2. Trastuzumab deruxtecan (T-DXd; DS-8201a; DS-8201) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
Cat. No.: HY-138298C
CAS No.: 1826843-81-5
Synonyms: T-DXd (DAR4); DS-8201 (DAR4); DS-8201a (DAR4)
Target:
Research Areas:
Trastuzumab deruxtecan (DAR4) (T-DXd (DAR4); DS-8201 (DAR4); DS-8201a (DAR4)) is a low-drug-load derivative control preparation of Trastuzumab deruxtecan (HY-138298A) with a drug-to-antibody ratio (DAR) of 4. Trastuzumab deruxtecan (T-DXd; DS-8201a; DS-8201) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
Cat. No.: HY-138298D
CAS No.: 1826843-81-5
Synonyms: T-DXd (DAR6); DS-8201 (DAR6); DS-8201a (DAR6)
Target:
Research Areas:
Trastuzumab deruxtecan (DAR6) (T-DXd (DAR6); DS-8201 (DAR6); DS-8201a (DAR6)) is a low-drug-load derivative control preparation of Trastuzumab deruxtecan (HY-138298A) with a drug-to-antibody ratio (DAR) of 6. Trastuzumab deruxtecan (T-DXd; DS-8201a; DS-8201) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
Cat. No.: HY-188016
CAS No.: 3086791-83-2
Target:
Research Areas:
MC-GGFG-TriPtolide is a peptide-drug conjugate (PDC) composed of a cell-penetrating peptide (MC), a cathepsin-cleavable GGFG peptide linker, and the payload drug Triptolide (HY-32735), and it is used for targeted intracellular delivery .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
